Early studies highlight the promise of prostate-specific membrane antigen–targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guided approaches, supported by high-quality clinical evidence, to translate feasibility into meaningful oncological benefits.
European Urology published a clinical update in Research Highlights on 14 Jan 2026.
The item focuses on The Hype and the Hope: Where Do We Stand with Prostate-specific Membrane Antigen–targeted Fluorescence-guided Surgery?.
Review the original article for the full source wording and details.